0001209191-23-048199.txt : 20230905
0001209191-23-048199.hdr.sgml : 20230905
20230905170845
ACCESSION NUMBER: 0001209191-23-048199
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Balthaser Kevin
CENTRAL INDEX KEY: 0001957554
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 231236810
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 640 LEE ROAD, SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-01
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001957554
Balthaser Kevin
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-09-01
4
M
0
1000
A
6256
D
Common Stock
2023-09-01
4
F
0
285
7.90
D
5971
D
Restricted Stock Units
2023-09-01
4
M
0
1000
0.00
D
Common Stock
1000
1000
D
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-09-05